Wall Street brokerages forecast that Joint Corp (NASDAQ:JYNT) will report $10.34 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Joint’s earnings. The highest sales estimate is $11.20 million and the lowest is $9.47 million. Joint reported sales of $7.56 million in the same quarter last year, which indicates a positive year over year growth rate of 36.8%. The business is scheduled to report its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that Joint will report full-year sales of $44.10 million for the current year, with estimates ranging from $40.89 million to $47.30 million. For the next financial year, analysts anticipate that the firm will report sales of $57.08 million, with estimates ranging from $54.45 million to $59.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Joint.

Joint (NASDAQ:JYNT) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.06. The business had revenue of $10.68 million for the quarter, compared to the consensus estimate of $8.90 million. Joint had a net margin of 4.50% and a return on equity of 115.44%.

JYNT has been the topic of a number of research reports. DA Davidson initiated coverage on shares of Joint in a report on Thursday, January 17th. They set a “buy” rating and a $10.00 target price on the stock. ValuEngine upgraded shares of Joint from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 20th. Maxim Group restated a “buy” rating and set a $18.00 target price (up previously from $11.00) on shares of Joint in a report on Friday, March 8th. Lake Street Capital boosted their target price on shares of Joint to $20.00 and gave the company a “buy” rating in a report on Friday, March 8th. Finally, Zacks Investment Research cut shares of Joint from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $18.40.

Joint stock traded up $1.00 during mid-day trading on Friday, reaching $19.43. 222,603 shares of the company traded hands, compared to its average volume of 109,623. Joint has a 52-week low of $6.51 and a 52-week high of $19.81. The company has a market cap of $267.84 million, a P/E ratio of 485.75, a PEG ratio of 8.41 and a beta of 0.86.

Hedge funds have recently made changes to their positions in the company. Marshall Wace North America L.P. bought a new position in Joint in the 1st quarter worth about $47,000. JPMorgan Chase & Co. bought a new position in Joint in the 1st quarter worth about $66,000. SEI Investments Co bought a new position in Joint in the 1st quarter worth about $67,000. Citigroup Inc. bought a new position in Joint in the 1st quarter worth about $133,000. Finally, Northern Trust Corp boosted its stake in Joint by 16.1% in the 4th quarter. Northern Trust Corp now owns 16,614 shares of the company’s stock worth $138,000 after purchasing an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 44.35% of the company’s stock.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Read More: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.